Minor Building
The IDIC is located in the Minor Building.

Explore How the IDIC Can Support Your Next Clinical Study

The Infectious Disease Innovation Center (IDIC) has state-of-the-art respiratory viral contamination and infectious disease expertise. Review our capabilities and services below. 

Interested in partnering with the IDIC? Please email us at IDIC@fredhutch.org

Clinical Research Capabilities 

Facilities and Equipment

  • Isolation-capable infrastructure to support safe interaction with participants with communicable diseases
  • Over 6,000 square feet of dedicated clinical research space 
  • 11 private clinic rooms with windowed doors for safe and discreet patient monitoring
  • Secure underground parking with direct access for study participants
  • Refrigerator, freezers and controlled room temperature cabinet
  • Biosafety cabinet
  • Centrifuge
  • GeneXpert diagnostic system, enabling rapid testing for pathogens including SARS-CoV-2, RSV, influenza and tuberculosis (TB)

Common Services

  • Participant screening, enrollment and follow-up
  • Clinical assessments, including general and focused history and physical exams
  • Phlebotomy and biospecimen collection
  • Rapid diagnostic testing
  • Biospecimen processing
  • Drug preparation 
  • EKGs and vital signs monitoring
  • Drug administration and safety assessments
exam room

Spacious Exam Rooms

biosafety cabinet

Lab Capabilities: Biosafety Cabinet

Lab Equipment

Lab Capabilities: Centrifuge

wall pass through

State of the art respiratory viral containment: Wall pass through for safe handling of product/samples between clinic zones

exam room

Spacious Exam Rooms

biosafety cabinet

Lab Capabilities: Biosafety Cabinet

Lab Equipment

Lab Capabilities: Centrifuge

wall pass through

State of the art respiratory viral containment: Wall pass through for safe handling of product/samples between clinic zones

Clinical Trial Information

Active Clinical Trials

  • GeoVax: A Phase 2 randomized, multi-center study of GEO-CMO4S1 (SARS-CoV-2 vaccine) versus mRNA SARS-CoV-2 vaccine in patients post cellular therapy for hematological malignancies. Investigator: Josh Hill, MD, FIDSA.
  • Moderna: A Phase 2 study of mRNA-1647 cytomegalovirus vaccine in pts who have undergone allogenic hematopoietic cell transplantation. Investigator: Michael Boeckh, MD, PhD.

Past Trials (not comprehensive)

  • AstraZeneca: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study (SUPERNOVA). Investigator: Jim Boonyaratanakornkit, MD, PhD.